Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study
Martee L. Hensley(Memorial Sloan Kettering Cancer Center), Matthew A. Powell(National Cancer Institute), Thomas Rutherford(University of South Florida), Lari Wenzel(University of California, Irvine), Richard P. Moser(National Cancer Institute), Gustavo C. Rodriguez(NorthShore University HealthSystem), Helen Huang(Roswell Park Comprehensive Cancer Center), Kelly‐Anne Phillips(The University of Melbourne), John F. Boggess(University of Kentucky), Robert M. Wenham(Moffitt Cancer Center), Joan L. Walker(Cornell University), Paul K. J. Han(National Cancer Institute), Mark H. Greene(Cancer Institute (WIA)), Chad A. Hamilton(Walter Reed National Military Medical Center), David E. Cohn(The Ohio State University), Noah D. Kauff(Cancer Institute (WIA)), Kelly J. Wilkinson(University of Mississippi Medical Center)
Cited by 14
Related Papers
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study
|The Lancet Oncology|2017|929
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660